Clinical Trials Logo

Adenocarcinoma clinical trials

View clinical trials related to Adenocarcinoma.

Filter by:

NCT ID: NCT06362070 Recruiting - Gastric Cancer Clinical Trials

Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Gastrectomy

Start date: January 31, 2024
Phase: N/A
Study type: Interventional

The object of this exploratory clinical trial is to evaluate intra and post-operative complications in a population that underwent Robotic Gastrectomy, with multiple platforms: - DaVinci; - Hugo; - Versius. This study is divided into two phases: in the first phase, gastrectomy will be performed using both the new platforms (Hugo and Versius) and the standard platform (Da Vinci), to evaluate the feasibility of the surgical procedure. In the second phase, the three platforms will be compared to evaluate any differences in the learning curve for an upper-GI surgeon, expert in laparoscopic surgery but not with robotic one. The questions it aims to answer are: - Are differences (intra-operative, post-operative, oncological, functional, technical, and economic) among the three different platforms observable? - Are there any differences between the three platforms related to the learning curve for surgeons? Participants will be enrolled, after obtaining informed consent, in one of the following cohorts: 1. surgery with the daVinci platform; 2. surgery with the Hugo platform; 3. surgery with the Versius platform.

NCT ID: NCT06361030 Not yet recruiting - Pancreatic Cancer Clinical Trials

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advance d pancreatic cancer

NCT ID: NCT06358001 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

EchoTip AcuCore Post-Market Clinical Study

Start date: June 1, 2024
Phase:
Study type: Observational

The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the EchoTip AcuCore.

NCT ID: NCT06356311 Not yet recruiting - Clinical trials for Gastroesophageal Cancer

A Study to Evaluate MK-2870 in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Start date: May 8, 2024
Phase: Phase 3
Study type: Interventional

This study will compare how safe and effective MK-2870 is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is MK-2870 is superior to TPC with respect to Overall Survival (OS).

NCT ID: NCT06353152 Recruiting - Clinical trials for Gastric Adenocarcinoma

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma

Start date: November 17, 2023
Phase: Phase 1
Study type: Interventional

A single-arm, open-label early-stage exploratory clinical study to evaluate the safety, tolerability and efficacy of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in subjects with gastric/gastroesophageal junction adenocarcinoma.

NCT ID: NCT06351020 Not yet recruiting - Clinical trials for Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy and safety of LM-302 Versus Treatment of Physician's Choice (TPC) in Subjects With locally advanced or metastatic, Claudin (CLDN) 18.2-positive, Gastric or Gastroesophageal Junction Adenocarcinoma who have progressed on or after 2 lines of systemic therapy

NCT ID: NCT06349044 Recruiting - Colorectal Cancer Clinical Trials

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Start date: March 20, 2024
Phase: N/A
Study type: Interventional

Based on the interaction between radiation therapy and immunotherapy and the potential potentiation of Probio-M9 for the treatment of ICIs, this study is planned to design an integrated treatment protocol for the first-line treatment of advanced gastrointestinal tumors through the use of macrofractionated radiotherapy as a means of immune activation, combined with the synergistic effect of Probio-M9 microbial agents and PD-1 inhibitors.

NCT ID: NCT06347809 Recruiting - Clinical trials for Prostate Adenocarcinoma

DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine

Start date: November 7, 2018
Phase:
Study type: Observational

This study explores the potential use of DNA markers in the detection of prostate cancer and patient perceptions of this screening approach and other current or future prostate cancer screening and diagnostic tests.

NCT ID: NCT06346392 Recruiting - Gastric Cancer Clinical Trials

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Start date: March 4, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.

NCT ID: NCT06346197 Not yet recruiting - Gastric Cancer Clinical Trials

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

CIME
Start date: May 15, 2024
Phase: Phase 3
Study type: Interventional

CIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the survival of patients suffering from MSI-H/dMMR locally advanced or metastatic oeasogastric adenocarcinoma treated by a bi-immunotherapy (experimental arm) versus standard current treatment (FOLFOX/XELOX + nivolumab : standard arm).